The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. - Concepedia

Concepedia

Publication | Closed Access

The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.

130

Citations

35

References

2006

Year

Josée Golay, Elena Cittera, Nicola Di Gaetano, Massimiliano Manganini, Michela Mosca, Manuela Nebuloni, Nico van Rooijen, Luca Vago, Martino Introna

Abstract

These data demonstrate that complement is required for the therapeutic activity of rituximab in vivo in a murine model of B-cell lymphoma, independently of its localization in lymph nodes or subcutaneously.

References

	Year	Citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Raphael Clynes, Terri L. Towers, Leonard G. Presta, Nature Medicine MedicineInhibitory Fc ReceptorsTumor TargetingAnti-cancer AgentPharmacology	2000	2.7K
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis Jonathan Edwards, L Szczepański, Jacek Szechiński, New England Journal of Medicine	2004	2.6K
Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity Robert L. Shields, Jadine Lai, Rodney G. Keck, Journal of Biological Chemistry ImmunotoxicologyImmunologyImmune RegulationHuman FcγriiiImmunologic Mechanism	2002	1.8K
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte Pierre Feugier, Ambro van Hoof, Catherine Sebban, Journal of Clinical Oncology	2005	1.5K
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma Wen‐Kai Weng, Ronald Levy Journal of Clinical Oncology	2003	1.3K
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy Junji Uchida, Yasuhito Hamaguchi, Julie A. Oliver, The Journal of Experimental Medicine	2004	627
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Blood	2000	568
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo Nicola Di Gaetano, Elena Cittera, Rachele Nota, The Journal of Immunology	2003	559
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Josée Golay, Manuela Lazzari, Valeria Facchinetti, Blood	2001	420
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Mark S. Cragg, Suzanne M. Morgan, H.T. Claude Chan, Blood	2003	380

Page 1